Profile
Chang Rung Chen was the founder of Processa Pharmaceuticals, Inc. (founded in 2011) where he held the title of Senior Director-Translational Science until 2022.
He also held the position of Director-Bimolecular Discovery at ArQule, Inc. and Director-Translational Research & Pharmacology at Questcor Pharmaceuticals, Inc. from 2015 to 2016.
Dr. Chen received his graduate and doctorate degrees from New York University and his undergraduate degree from Tunghai University.
Former positions of Chang Rung Chen
Companies | Position | End |
---|---|---|
PROCESSA PHARMACEUTICALS, INC. | Founder | 01/11/2022 |
QUESTCOR PHARMACEUTICALS INC | Corporate Officer/Principal | 01/01/2016 |
ARQULE, INC. | Corporate Officer/Principal | - |
Training of Chang Rung Chen
New York University | Doctorate Degree |
Tunghai University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
PROCESSA PHARMACEUTICALS, INC. | Health Technology |
Private companies | 2 |
---|---|
ArQule, Inc.
ArQule, Inc. Pharmaceuticals: MajorHealth Technology ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company was founded in 1993 and is headquartered in Burlington, MA. | Health Technology |
Questcor Pharmaceuticals, Inc.
Questcor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Questcor Pharmaceuticals, Inc. was engaged in development, marketing and sale of prescription drugs. It operated as a biopharmaceutical company which focuses on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. The company's primary product was H.P. Acthar Gel, an injectable drug for the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. Questcor Pharmaceuticals was founded in September 1992 and was headquartered in Anaheim, CA. | Health Technology |
- Stock Market
- Insiders
- Chang Rung Chen